EGFR Cancer Research Results

EGFR, Epidermal Growth Factor Receptor: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-Driver
Type: Oncogene
EGFR (Epidermal growth factor receptor), which belongs to the tyrosine kinase receptor family (RTKs)
Epidermal Growth Factor Receptor (EGFR) is a cell surface protein that plays a crucial role in the regulation of cell growth, survival, proliferation, and differentiation. It is part of the ErbB family of receptors and is activated by binding to its ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).

-plays a crucial role in regulating cell growth and division.

Many cancers exhibit overexpression of EGFR, which can lead to enhanced signaling and contribute to tumor growth and survival. This overexpression is often associated with aggressive tumor behavior and poor prognosis.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
2694- BBR,    Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells
- in-vitro, BC, NA
IL8↓, TumCI↓, EGFR↓, MEK↓, ERK↓, TGF-β1↓, VEGF↓,
5721- BF,    Bufalin Suppresses Triple-Negative Breast Cancer Stem Cell Growth by Inhibiting the Wnt/β-Catenin Signaling Pathway
- in-vitro, BC, NA
CSCs↓, TumCCA↑, cMyc↓, cycD1/CCND1↓, CDK4↓, MMP↓, Casp↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, SOX2↓, Wnt↓, β-catenin/ZEB1↓, EGFR↓,
13- CUR,    Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action
- Review, BC, NA
P53↑, DR5↑, JNK↑, NRF2↑, PPARγ↑, HER2/EBBR2↓, IR↓, ER(estro)↓, Fas↑, PDGF↓, TGF-β↓, FGF↓, EGFR↓, JAK↓, PAK↓, MAPK↓, ATPase↓, COX2↓, MMPs↓, IL1↓, IL2↓, IL5↓, IL6↓, IL8↓, IL12↓, IL18↓, NF-kB↓, NOTCH1↓, STAT1↓, STAT4↓, STAT5↓, STAT3↓,
1443- Deg,    Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, BT549
EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,
668- EGCG,    The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment
- Review, BC, MCF7 - Review, BC, MDA-MB-231
HER2/EBBR2↓, EGFR↓, mtDam↑, ROS↑, PI3K/Akt↓, P53↑, P21↑, Casp3↑, Casp9↑, BAX↑, PTEN↑, Bcl-2↓, hTERT/TERT↓, STAT3↓, TumCCA↑, Hif1a↓,
7456- HNK,    Honokiol in the treatment of triple-negative breast cancer: a network pharmacology approach and experimental validation
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
Apoptosis↑, TumCMig↓, TumCP↓, HSP90↓, AKT1↓, EGFR↓, HSP90↓, MDM2↓, HDAC1↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
62- QC,  GoldNP,    Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231)
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
EGFR↓, PI3k/Akt/mTOR↓, GSK‐3β↓, TumCP↓, Apoptosis↑, tumCV↓, mTOR↓, PTEN↑,
2414- β‐Ele,    Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

Showing Research Papers: 1 to 10 of 10

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 10

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

NRF2↑, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   MMP↓, 1,   mtDam↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   AMPK↑, 2,   cMyc↓, 2,   ECAR↓, 1,   FDG↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   IR↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PDH↑, 1,   PI3K/Akt↓, 1,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 1,   PPARγ↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 4,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 1,   Casp3↑, 1,   Casp9↑, 1,   DR5↑, 1,   Fas↑, 1,   hTERT/TERT↓, 1,   JNK↑, 1,   MAPK↓, 1,   MDM2↓, 1,   Myc↓, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 2,   PAK↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 2,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CD44↓, 1,   cMET↓, 2,   CSCs↓, 1,   ERK↓, 1,   p‑ERK↓, 1,   FGF↓, 1,   GSK‐3β↓, 1,   HDAC1↓, 1,   mTOR↓, 2,   Nanog↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   PTEN↑, 2,   SOX2↓, 1,   STAT1↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   STAT4↓, 1,   STAT5↓, 1,   TumCG↓, 2,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

ATPase↓, 1,   MMPs↓, 1,   PDGF↓, 1,   TGF-β↓, 1,   TGF-β1↓, 1,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 4,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 10,   EGR4↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IL1↓, 1,   IL12↓, 1,   IL18↓, 1,   IL2↓, 1,   IL5↓, 1,   IL6↓, 1,   IL8↓, 2,   JAK↓, 1,   NF-kB↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ER(estro)↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   eff↓, 1,   Half-Life↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 10,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 1,   IL6↓, 1,   Myc↓, 1,  
Total Targets: 103

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSH↑, 1,   lipid-P↓, 1,   ROS↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 1,   other↓, 1,   other↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

ChAT↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↝, 1,   Half-Life↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

memory↑, 1,   neuroP↑, 1,  
Total Targets: 18

Scientific Paper Hit Count for: EGFR, Epidermal Growth Factor Receptor
1 Alpha-Lipoic-Acid
1 Berberine
1 Bufalin/Huachansu
1 Curcumin
1 Deguelin
1 EGCG (Epigallocatechin Gallate)
1 Honokiol
1 Piperlongumine
1 Quercetin
1 Gold NanoParticles
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:94  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page